[Androgen deprivation therapy for prostate cancer and osteoporotic risk]. / Suppression androgénique dans le cancer de la prostate et risque ostéoporotique.
Prog Urol
; 22 Suppl 2: S31-8, 2012 Sep.
Article
em Fr
| MEDLINE
| ID: mdl-23098788
ABSTRACT
Androgen deprivation therapy represents an important part of the management of prostate cancer. However, epidemiological data have shown that it is a well-established cause of osteoporosis and increased risk of fracture. So far no consensus guidelines have been published regarding the screening and treatment of osteoporosis in men with prostate cancer. Here we report the design of a new questionnaire, derived from the FRAX(®) ("Fracture Risk Assessment Tool") algorithm, to evaluate the risk of fracture in those patients. In accordance with recent reviews and on the basis of their experience, our French board of experts recommends systematic screening for osteoporosis with dual energy x- ray absorptiometry scans, practice of exercise and calcium and vitamin D supplementation, and selective treatment with bisphosphonates in men at greatest osteoporotic risk.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Osteoporose
/
Neoplasias da Próstata
/
Antagonistas de Androgênios
Tipo de estudo:
Etiology_studies
/
Guideline
/
Qualitative_research
/
Risk_factors_studies
Limite:
Humans
/
Male
Idioma:
Fr
Revista:
Prog Urol
Assunto da revista:
UROLOGIA
Ano de publicação:
2012
Tipo de documento:
Article
País de afiliação:
França